Advertisement
With the start of 2009, all business will be managed under the namePharmatech Oncology, Inc. The Pharmatech Board of Directors implemented thename change from the parent company of Pharmatech, Inc. to the subsidiary nameof Pharmatech Oncology. Anders Malm, current President, states, "There was aneed in the marketplace for better recognition of what type of businessPharmatech was involved in. Changing from Pharmatech to Pharmatech Oncologyrelays a core understanding that Pharmatech works within the cancer arena."
Advertisement
The leadership team at Pharmatech Oncology will also be undergoing atransformation in roles and titles. Current Chief Executive Officer, MatthewB. Wiener, PharmD, will now take over the daily business operations under thetitle Chairman and Chief Operating Officer. Anders Malm, current President,will now replace Dr. Wiener as CEO. Pharmatech Oncology also welcomes RobBohacs as the new Corporate Development Manager.
Pharmatech Oncology will also introduce a new web site,http://www.pharmatechoncology.com. The launch of the new web site willshowcase a more functional format, along with easy navigation capabilities.The current web site http://www.pharmatech.com will point to the new addressat http://www.pharmatechoncology.com.
About Pharmatech Oncology:
Pharmatech Oncology, headquartered in Denver, Colorado, is a ResearchManagement Organization (RMO) dedicated to the highest quality of clinicalresearch. Pharmatech Oncology provides services of a Site ManagementOrganization (SMO) and a Contract Research Organization (CRO) with a focus inoncology clinical trials. Through an organized research network, the Companyfocuses on the development and utilization of therapeutic products amongsponsors, investigators, and patients. For more information about PharmatechOncology, please visit www.pharmatechoncology.com.
SOURCE Pharmatech, Inc.
